DE69023900T2 - Gentechnologisch veränderte immunglobuline. - Google Patents

Gentechnologisch veränderte immunglobuline.

Info

Publication number
DE69023900T2
DE69023900T2 DE69023900T DE69023900T DE69023900T2 DE 69023900 T2 DE69023900 T2 DE 69023900T2 DE 69023900 T DE69023900 T DE 69023900T DE 69023900 T DE69023900 T DE 69023900T DE 69023900 T2 DE69023900 T2 DE 69023900T2
Authority
DE
Germany
Prior art keywords
genetically modified
modified immunoglobulins
preparing
found
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69023900T
Other languages
English (en)
Other versions
DE69023900D1 (de
DE69023900T4 (de
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69023900(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of DE69023900T2 publication Critical patent/DE69023900T2/de
Application granted granted Critical
Publication of DE69023900T4 publication Critical patent/DE69023900T4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69023900T 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline. Expired - Lifetime DE69023900T4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24
PCT/US1990/001010 WO1990009804A1 (en) 1989-02-24 1990-02-23 Genetically engineered immunoglobulins

Publications (2)

Publication Number Publication Date
DE69023900T2 true DE69023900T2 (de) 1996-07-04
DE69023900T4 DE69023900T4 (de) 1996-10-02

Family

ID=23227670

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69023900T Expired - Lifetime DE69023900T4 (de) 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline.
DE69023900A Expired - Fee Related DE69023900D1 (de) 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69023900A Expired - Fee Related DE69023900D1 (de) 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline.

Country Status (9)

Country Link
US (3) US5508386A (de)
EP (1) EP0460076B1 (de)
JP (2) JP3355351B2 (de)
AT (1) ATE130765T1 (de)
CA (1) CA2047244C (de)
DE (2) DE69023900T4 (de)
DK (1) DK0460076T3 (de)
ES (1) ES2082850T3 (de)
WO (1) WO1990009804A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6241985B1 (en) * 1996-05-15 2001-06-05 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
AU763029B2 (en) * 1997-11-14 2003-07-10 Euro-Celtique S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
EP1042459A4 (de) * 1997-12-24 2003-07-23 Diatech Pty Ltd Bifunktionelle moleküle
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
AU753753B2 (en) * 1998-11-13 2002-10-24 Euro-Celtique S.A. Contraceptive antibody vaccines
US7439233B1 (en) * 1999-02-25 2008-10-21 Tai June Yoo Vaccine for house dust mite allergen using naked DNA
CA2369616C (en) * 1999-04-27 2009-09-15 Eurogen Holding, S.A. Somatic transgene immunization and related methods
EP1246643A4 (de) 1999-10-14 2005-05-11 Jeffery A Ledbetter Dna impfstoffe, welcheein antigen kodieren, dass an eine cd40-bindende domäne bindet
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
AU5697001A (en) * 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2003002908A1 (en) * 2000-06-26 2003-01-09 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
AU2002307062A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
EP2258712A3 (de) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
CA2481437A1 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
AR039429A1 (es) * 2002-04-19 2005-02-16 Endocyte Inc Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
WO2004087877A2 (en) * 2003-03-26 2004-10-14 Astral Inc. Selected rna motifs to include cell death and/or apoptosis
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
NZ560535A (en) * 2005-01-13 2011-01-28 Novartis Vaccines & Diagnostic Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (de) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
EP2282753A1 (de) * 2008-04-30 2011-02-16 Novartis AG Assay für pathogene conformer
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381494D1 (de) * 1982-11-30 1990-05-31 Pasteur Institut Immunogen-lage des poliovirus enthaltende peptide und dns enthaltend nukleotidfragmente die fuer diese peptide kodieren.
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
WO1992018540A1 (en) * 1991-04-18 1992-10-29 Mount Sinai School Of Medicine Of The City University Of New York Anti-human immunodeficiency virus recombinant antibodies

Also Published As

Publication number Publication date
EP0460076B1 (de) 1995-11-29
ES2082850T3 (es) 1996-04-01
JP2001190295A (ja) 2001-07-17
CA2047244C (en) 2002-09-17
DE69023900D1 (de) 1996-01-11
JP3357890B2 (ja) 2002-12-16
ATE130765T1 (de) 1995-12-15
JP3355351B2 (ja) 2002-12-09
JPH04503605A (ja) 1992-07-02
EP0460076A4 (en) 1992-08-05
US5508386A (en) 1996-04-16
DE69023900T4 (de) 1996-10-02
DK0460076T3 (da) 1996-03-25
WO1990009804A1 (en) 1990-09-07
EP0460076A1 (de) 1991-12-11
US5583202A (en) 1996-12-10
CA2047244A1 (en) 1990-08-25
US5658762A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
DE69023900D1 (de) Gentechnologisch veränderte immunglobuline.
HK129394A (en) Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
SE9201331D0 (sv) Protein l och hybridproteiner daerav
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
DE3750339D1 (de) HTLV-III umhüllende Peptiden.
DE69535719D1 (de) Fas-antigenbindender ligand
PT96097A (pt) Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
ATE148168T1 (de) Monoklonale antikörper
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
FI103730B1 (fi) Molekyylikloonauksella aikaansaadut haiman saarekesoluantigeenit
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
DE68907735T2 (de) Genfragmente, die die variable Region eines Anti-HIV-Antikörpers codieren, von diesen exprimierte chimäre Anti-HIV-Antikörper und Verfahren zu deren Herstellung.
ATE233811T1 (de) Blutplaettchen-gpiiia p1a1 und -p1a2-epitope, ihre herstellung und verwendung
NO174153C (no) Antigen og monoklonalt antistoff for anvendelse in vitro, samt immunologiske reagenser inneholdende disse
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
Wollheim et al. Studies on the Macroglobulins of Human Serum IV: The Frequency of Light Chain Types K and L in Polyclonal and Monoclonal γM.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
NO912192D0 (no) Rekombinante dna og fremgangsmaate for fremstilling av chimere antistoffer.
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.